Curative Biotechnology Inc (CUBT)

[BokehRebl]

Everything you say is correct in my opinion except believing that CTYX will have rights to IMT504 to develop other treatments then for rabies. Mid-Atlantic Bio’s entire business is centred around this immunotherapy, I believe Mid-Atlantic Bio developed it to then license it to other developers to create solutions. Example their website states it could be useful for covid, if someone would license IMT504 for covid purposes they could develop it for this but nothing else.

« Company has signed a term sheet with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire all necessary rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies worldwide.«